Opiant Pharmaceuticals Inc. (OPNT)

10.59
0.23 2.13
NASDAQ : Health Technology
Prev Close 10.82
Open 10.67
Day Low/High 10.23 / 10.80
52 Wk Low/High 10.00 / 29.55
Volume 23.63K
Avg Volume 22.40K
Exchange NASDAQ
Shares Outstanding 4.00M
Market Cap 43.71M
EPS -7.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For New NARCAN® Nasal Spray Patent

Listing Bolsters IP Estate and Enhances NARCAN Product Exclusivity

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings For Two New NARCAN® Nasal Spray Patents

Listings Significantly Strengthen IP Estate and Enhance NARCAN Product Exclusivity

Opiant Pharmaceuticals, Inc. Receives FDA Feedback Supporting Clinical Development Of OPNT002 For The Treatment Of Alcohol Use Disorder

Company Plans Additional Clinical Trials This Year; Topline Data Expected in 2018

Opiant Pharmaceuticals, Inc. Announces Establishment Of Audit, Compensation And Nominating And Corporate Governance Committees

Company to pursue up-listing to a major stock exchange in 2017

Opiant Pharmaceuticals, Inc. Announces FDA Approval Of 2mg Formulation Of NARCAN (naloxone HCI) Nasal Spray

Opiant Pharmaceuticals, Inc. Announces FDA Approval Of 2mg Formulation Of NARCAN (naloxone HCI) Nasal Spray

2mg Formulation Indicated for Patients At-Risk for Severe Opioid Withdrawal

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization

Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization

SWK to Acquire Certain NARCAN® Royalties For Up to $17.5 Million

Opiant Pharmaceuticals, Inc. Announces Appointment Of Thomas T. Thomas To Board Of Directors

Opiant Pharmaceuticals, Inc. Announces Appointment Of Thomas T. Thomas To Board Of Directors

Thomas Brings Global Pharmaceutical and Financial Expertise to Opiant's Board

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For Narcan® Nasal Spray Patent

Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing For Narcan® Nasal Spray Patent

Listing Offers Product Exclusivity Until 2035

Opiant Pharmaceuticals, Inc. Announces Appointments Of Gabrielle A. Silver, M.D., And Ann MacDougall To Board Of Directors

Opiant Pharmaceuticals, Inc. Announces Appointments Of Gabrielle A. Silver, M.D., And Ann MacDougall To Board Of Directors

Board Appointments Reflect Opiant's Development as a Commercial-Stage Pharmaceutical Company

Faruqi & Faruqi, LLP Is Seeking More Cash For The Shareholders Of OPNET Technologies Inc. (OPNT)

Faruqi & Faruqi, LLP Is Seeking More Cash For The Shareholders Of OPNET Technologies Inc. (OPNT)

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of OPNET Technologies Inc.

Law Office Of Brodsky & Smith, LLC Announces Investigation Of OPNET Technologies, Inc.

Law Office Of Brodsky & Smith, LLC Announces Investigation Of OPNET Technologies, Inc.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of OPNET Technologies, Inc.

Ryan & Maniskas, LLP Announces Investigation Of OPNET Technologies, Inc.

Ryan & Maniskas, LLP Announces Investigation Of OPNET Technologies, Inc.

Ryan & Maniskas, LLP ( www.rmclasslaw.

OPNET Technologies Investor Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Sale To Riverbed Technology

OPNET Technologies Investor Alert: Briscoe Law Firm And Powers Taylor, LLP Investigate Sale To Riverbed Technology

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of OPNET Technologies, Inc.